These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 22217713)

  • 1. Cooperative antitumor effect of endothelial-monocyte activating polypeptide II and flutamide on human prostate cancer xenografts.
    Reznikov AG; Chaykovskaya LV; Polyakova LI; Kornelyuk AI; Grygorenko VN
    Exp Oncol; 2011 Dec; 33(4):231-4. PubMed ID: 22217713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model.
    Reznikov AG; Chaykovskaya LV; Polyakova LI; Kornelyuk AI
    Exp Oncol; 2007 Dec; 29(4):267-71. PubMed ID: 18199981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of cytokine-like polypeptide EMAP II and flutamide on the testosterone-stimulated prostate of castrated rats].
    Reznikov OH; Chaĭkovs'ka LV; Poliakova LI; Sachyns'ka OV
    Fiziol Zh (1994); 2011; 57(4):12-20. PubMed ID: 22164405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
    Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
    Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.
    Awasthi N; Schwarz MA; Schwarz RE
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):571-82. PubMed ID: 21110024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II.
    Schwarz RE; Schwarz MA
    J Surg Res; 2004 Jul; 120(1):64-72. PubMed ID: 15172191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive effect of low-frequency ultrasound and endothelial monocyte-activating polypeptide II on blood-tumor barrier in rats with brain glioma.
    Zhang Z; Xue Y; Liu Y; Shang X
    Neurosci Lett; 2010 Aug; 481(1):21-5. PubMed ID: 20600613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature.
    Kayton ML; Libutti SK
    Curr Opin Investig Drugs; 2001 Jan; 2(1):136-8. PubMed ID: 11527006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-neoplastic activity of low-dose endothelial-monocyte activating polypeptide-II results from defective autophagy and G2/M arrest mediated by PI3K/Akt/FoxO1 axis in human glioblastoma stem cells.
    Liu J; Liu L; Xue Y; Meng F; Li S; Wang P; Liu Y
    Biochem Pharmacol; 2014 Jun; 89(4):477-89. PubMed ID: 24792437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
    Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
    Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
    Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
    Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB; Isaacs JT
    Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
    Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M; Latham DE; Delaney MA; Chakravarti A
    Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer.
    Schwarz RE; Konduri S; Awasthi N; Cafasso D; Schwarz MA
    Surgery; 2009 Aug; 146(2):241-9. PubMed ID: 19628080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.
    Berger AC; Alexander HR; Tang G; Wu PS; Hewitt SM; Turner E; Kruger E; Figg WD; Grove A; Kohn E; Stern D; Libutti SK
    Microvasc Res; 2000 Jul; 60(1):70-80. PubMed ID: 10873516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte- activating polypeptide II (EMAP-II).
    Berger AC; Alexander HR; Wu PC; Tang G; Gnant MF; Mixon A; Turner ES; Libutti SK
    Cytokine; 2000 Jul; 12(7):992-1000. PubMed ID: 10880244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
    Terada N; Shimizu Y; Yoshida T; Maeno A; Kamba T; Inoue T; Nakamura E; Kamoto T; Ogawa O
    Prostate; 2010 Feb; 70(3):252-61. PubMed ID: 19790238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.